Tracks outcomes of blood-thinning pills in heart rhythm and clot patients
Observes people with atrial fibrillation or blood clots taking newer anticoagulant pills.
Plain-language title generated from the registry record
Registry title: NOACs Use in AF or VTE (SUNSHINE Registry)
Key facts
- Where
- Zhengzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for people with atrial fibrillation (AF) or a blood clot in a vein (VTE) who took a blood thinner in the last 3 months. It follows how these medicines work in everyday care.
- Sex
- All sexes can join.
- Disease stage
- Atrial fibrillation diagnosed by a doctor, or a new or repeat acute blood clot in a vein (VTE).
- Earlier treatment
- Must have taken a blood thinner (a NOAC or a VKA) within the last 3 months.
Main reasons for not taking part
- AF caused by a reversible cause, such as thyroid disease or AF after surgery
- AF linked to a heart valve problem (rheumatic valve disease, mechanical heart valve)
- Taking part in another ongoing trial in AF or VTE
- Other reasons for blood thinners besides AF or VTE
- Incomplete information in the medical record
Read by machine on 9 November 2026.
Where in China
- Henan Provincial People's HospitalZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Henan Provincial People's Hospital
- Trial code
- NCT05378308
- Record updated
- 9 June 2022
- Original description
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient/outpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection and analysis of observational data in medical records from hospital information system (HIS) to evaluate the outcomes related with these NOACs when applied in extensive patient populations outside of clinical research studies. The registry will also allow for mainly combining the atrial fibrillation (AF) and venous thromboembolism (VTE) databases. In brief, the SUNSHINE registry will provide important information on the outcomes of NOACs in routine practice and gather further information on its safety and effectiveness.Read full original descriptionShow less
Outcomes regiStry for Non-vitamin k Antagonist Oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for Better cliNical practicE (SUNSHINE)
The outcomes regiStry for non-vitamin k antagonist oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for better cliNical practicE (SUNSHINE) is a multicenter, prospective, observational non-interventional inpatient/outpatient disease registry to assess the utilization of Non-vitamin k antagonist oral anticoagulants (NOACs), and associated outcomes. The SUNSHINE registry will focus on the collection and analysis of observational data in medical records from hospital information system (HIS) to evaluate the outcomes related with these NOACs when applied in extensive patient populations outside of clinical research studies. The registry will also allow for mainly combining the atrial fibrillation (AF) and venous thromboembolism (VTE) databases. In brief, the SUNSHINE registry will provide important information on the outcomes of NOACs in routine practice and gather further information on its safety and effectiveness.
Inclusion: Patients with clinically diagnosed with AF (eg, by electrocardiogram, Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE); Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months; Patients can be enrolled from both inpatient or outpatient settings.
Exclusion: AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF); Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease [predominantly mitral stenosis] or mechanical heart valves); Patients participating in an ongoing clinical trial in AF or VTE; Have Multiple anticoagulation indications apart from AF or VTE; Patients with incomplete information (illogical data, missing or insufficient data).